Edwards Lifesciences Valuation
Is EW * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EW * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EW * (MX$1538.57) is trading above our estimate of fair value (MX$1050.31)
Significantly Below Fair Value: EW * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EW *?
Other financial metrics that can be useful for relative valuation.
What is EW *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$51.73b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 8.3x |
Enterprise Value/EBITDA | 26.5x |
PEG Ratio | 3.8x |
Price to Earnings Ratio vs Peers
How does EW *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 46.9x | ||
300760 Shenzhen Mindray Bio-Medical Electronics | 30.3x | 15.0% | CN¥368.6b |
IDXX IDEXX Laboratories | 46.4x | 9.9% | US$39.9b |
DXCM DexCom | 79.3x | 18.3% | US$51.7b |
SHL Siemens Healthineers | 31.5x | 17.3% | €57.9b |
EW * Edwards Lifesciences | 36.6x | 9.8% | Mex$51.7b |
Price-To-Earnings vs Peers: EW * is good value based on its Price-To-Earnings Ratio (36.6x) compared to the peer average (49x).
Price to Earnings Ratio vs Industry
How does EW *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: EW * is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the Global Medical Equipment industry average (29x).
Price to Earnings Ratio vs Fair Ratio
What is EW *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 36.6x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EW *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.